Live birth

Carrot Fertility Exceeds National Benchmarks for Fertility Success, Publishes New, Independently Validated Outcomes Study

Retrieved on: 
Wednesday, January 18, 2023
PGT, Education, Menopause, Live birth, Embryo, Society, Death, IVF, SET, Risk, Pregnancy, Publishing, Assisted reproductive technology, Milliman, SART, Snap Inc., Fertility, Birth control, Medicine, Health insurance, Carrot

MENLO PARK, Calif., Jan. 18, 2023 /PRNewswire/ -- Carrot Fertility, the leading global platform for fertility healthcare and family-forming benefits, announced today the publishing of the Carrot Study, demonstrating that Carrot exceeds national benchmarks for fertility success and has a single embryo transfer (SET) rate of 93%, the highest reported of any fertility benefits solution with published outcomes. The study concludes that Carrot's flexible plan design can meaningfully improve medical outcomes, including healthy pregnancies and successful future live births, without also contributing to the overuse of expensive and sometimes unnecessary interventions. 

Key Points: 
  • MENLO PARK, Calif., Jan. 18, 2023 /PRNewswire/ -- Carrot Fertility , the leading global platform for fertility healthcare and family-forming benefits, announced today the publishing of the Carrot Study , demonstrating that Carrot exceeds national benchmarks for fertility success and has a single embryo transfer (SET) rate of 93%, the highest reported of any fertility benefits solution with published outcomes.
  • For this study, Carrot's Global Clinical Outcomes Division tracked the fertility outcomes of members enrolled in Carrot's benefits program and compared this data against national data from the Society for Assisted Reproductive Technology (SART).
  • To evaluate the methodology that Carrot used to track and compare its key outcomes against national benchmarks, Carrot engaged Milliman, Inc., an independent global leader in actuarial services.
  • "At Carrot, we've curated and manage the largest network of high-quality fertility clinics in the U.S. that provide the best possible care to our members," said Tammy Sun, Founder and CEO, Carrot Fertility.

Intrauterine Insemination (IUI) Success can be Predicted with a New IUI Assessment Released by Posterity Health and Path Fertility

Retrieved on: 
Wednesday, January 4, 2023
Family, Health, Consumer, Baby, Maternity, General Health, Men, Semen analysis, Education, IVF, Infertility, OBGYN, Conception, Female, Male, Fertility, Health, Excellent, Semen, Pregnancy, Patient, Reis, Entrepreneurship, Poverty, REI, IUI, Live birth, Reproductive health, Birth control

Together the companies offer a new comprehensive IUI Assessment that evaluates multiple semen parameters and predicts the likelihood of success with intrauterine insemination (IUI).

Key Points: 
  • Together the companies offer a new comprehensive IUI Assessment that evaluates multiple semen parameters and predicts the likelihood of success with intrauterine insemination (IUI).
  • By combining the two tests Posterity Health and Path Fertility provide the most complete and cutting-edge assessment of male reproductive health.
  • “The studies to date show that the integrated IUI Assessment is highly predictive of pregnancy outcomes with IUI.
  • Couples who complete the IUI Assessment earlier in the conception journey will benefit emotionally and financially by understanding the likelihood of IUI success.

RMA of New York Presents Ground-Breaking Research at ASRM 2022

Retrieved on: 
Monday, October 24, 2022
Physician, RNA transfection, Infertility, Review, Woman, Science, Gynaecology, Machine learning, Vaccine, Algorithm, Reproductive medicine, Society, Patient, Research, Division, Artificial intelligence, Probability, Birth weight, American Society for Reproductive Medicine, Oocyte, TGD, Mount Sinai Hospital, Big data, CEO, Mount Sinai, Egg, IVF, Congress, Association, Icahn School of Medicine at Mount Sinai, Vaccination, Fertility, ASRM, Live birth, COVID-19, Pregnancy, RMA, Fertility preservation, FACOG, Birth control, Obstetrics, Medicine, New York (magazine), MD

ANAHEIM, Calif., Oct. 24, 2022 /PRNewswire/ -- Physicians and scientists at RMA of New York (Reproductive Medicine Associates of New York) and the Icahn School of Medicine at Mount Sinai Hospital in New York proudly presented 21 original scientific abstracts at the 78th annual American Society for Reproductive Medicine (ASRM) congress in Anaheim, California. Research topics included live birth outcomes after COVID-19 vaccination, reproductive outcomes following transfer of embryos created from frozen eggs, and access to fertility care for trans- and gender-diverse patients.

Key Points: 
  • This study complements Dr. Aharon's previous research, which demonstrated no correlation between the mRNA COVID-19 vaccines and the implantation rate of euploid embryos.
  • RMA of New York is at the forefront of groundbreaking research in infertility and reproductive medicine, and is committed to advancing science for the treatment of infertility.
  • For the past 20+ years, the physicians of RMA of New York have consistently been distinguished as Top Doctors and Super Doctors by Castle Connolly and New York Magazine.
  • Headquartered in Midtown Manhattan, RMA of New York has fertility clinic locations throughout Manhattan, Brooklyn, Westchester, Long Island, and abroad in Mexico City.

Inception Fertility's Chief Executive Physician Leads Groundbreaking Study on Fertility Preservation

Retrieved on: 
Tuesday, June 28, 2022
Department, Fertility preservation, Science, Patient, CEO, Reproductive health, Aspire, Singleton, PGT, Research, Department of Obstetrics and Gynecology (Massachusetts General Hospital), Egg, Live birth, Gynaecology, IVF, Geographic Locator Codes, Medicine, Inception, Division, Ecosystem, Industry, Obstetrics, NYU Langone Health, Carolyn, MPH, ART, Woman, NYU, Center, Nursing, Doctor of Philosophy, Child, New York University Grossman School of Medicine, Leadership, Infertility, Birth control, Vaccine, Medical device, Fertility, MD

HOUSTON, June 28, 2022 /PRNewswire/ -- NYU Langone Fertility Center, a member of Inception Fertility's network of clinical practices, in conjunction with NYU Grossman School of Medicine, released the largest U.S. report of elective fertility preservation outcomes to date. Inception is the largest provider of comprehensive fertility services in North America. The results of this research were recently published in Fertility and Sterility.

Key Points: 
  • "The results of this groundbreaking study further amplify that fertility preservation is a viable option for women who want to take control over their fertility and expand their options, empowering them to make reproductive choices that are best for them," said Dr. Grifo.
  • "Inception Fertility congratulates Dr. Grifo and his colleagues at NYU Langone Fertility Center and NYU Grossman School of Medicine for this unprecedented study and for moving the fertility industry forward by confirming that women have viable choices when it comes to their reproductive health," said TJ Farnsworth, Founder and CEO of Inception Fertility.
  • The entire team of embryologists, doctors, nurses and support staff at the NYU Langone Fertility Center contributed to the success presented in this study.
  • Inception Fertility (Inception) is a family of fertility brands committed to helping patients build their own families.

Frozen Eggs More Efficient Option than IVF for Women Starting Families Later

Retrieved on: 
Friday, May 27, 2022
Department, IVF, Disease, Doctor of Philosophy, United States Census Bureau, Cryopreservation, Singleton, Woman, Patient, Center for Economic Studies (U.S. Census Bureau), Nursing, Fertility clinic, NYU, MPH, Live birth, Obstetrics, Child, NYU Langone Health, Center, Gynaecology, Department of Obstetrics and Gynecology (Massachusetts General Hospital), Technology, Freezing, Fertility, Division, Geographic Locator Codes, Egg, New York University Grossman School of Medicine, Carolyn, Birth control, Medical device, Infertility, MD

Egg freezing and thawing at a later date provides a higher pregnancy success rate than using fresh embryos during assisted reproductive technology, say the study authors.

Key Points: 
  • Egg freezing and thawing at a later date provides a higher pregnancy success rate than using fresh embryos during assisted reproductive technology, say the study authors.
  • The Center has seen almost triple the number of women starting egg freezing cycles in 2022 in comparison to 2019.
  • In fact, 14 patients who froze eggs at the age of 4143 years successfully had children from their frozen eggs.
  • "Freezing eggs at a young age becomes an option to be one's own egg donor at advanced age.

Fairtility™ Closes $15 Million Series A Funding Round

Retrieved on: 
Monday, May 23, 2022
Senior, Embryology, Population, Medicine, IVF, Infertility, TEL, Family, Patient, Health, Solution, Fertility clinic, Live birth, Method, Efficiency, Technology, Intuition, Adoption, LinkedIn, Twitter, Entrepreneurship, Transparency, CEO, Medical device, Mineral oil, AI

TEL AVIV, Israel, May 23, 2022 /PRNewswire/ -- Fairtility™ , the transparent AI innovator powering in vitro fertilization (IVF) for improved outcomes, today announced the completion of a $15 million Series A funding round, bringing total funding to $18.5 million to date. The round was led by Boston based, Gurnet Point Capital, and included Nacre Capital and additional investors.

Key Points: 
  • Funding Supports Further Development of Transparent AI Platform Designed to Improve IVF Outcomes, Starting with CHLOE EQ, Fairtility's Embryo Quality Assessment Assistant
    TEL AVIV, Israel, May 23, 2022 /PRNewswire/ -- Fairtility , the transparent AI innovator powering in vitro fertilization (IVF) for improved outcomes, today announced the completion of a $15 million Series A funding round, bringing total funding to $18.5 million to date.
  • The round was led by Boston based, Gurnet Point Capital, and included Nacre Capital and additional investors.
  • Fairtility is investing resources from its Series A funding round into advanced clinical research with fertility clinics and marquee academic institutions globally, as well as in regulatory approval processes.
  • To learn more about Fairtility or schedule a demo, visit our website and follow us on Twitter and LinkedIn .

'What is the Clinical Value of Day 7 Blastocysts?' New Study Makes Case for Culturing Embryos Up to Seven Days Post-Insemination for Selected Patients

Retrieved on: 
Tuesday, May 3, 2022
Child, Genetic testing, LBS, Culture, Twitter, Failure, IVF, Health, Pregnancy, Research, Data collection, Patient, Infertility, TEL, Live birth, Angelo Cimadomo, Artificial intelligence, International Institute of Rehabilitation Sciences and Research, Observational study, LinkedIn, Rienzi, CEO, Technology, Portrait, Generalife, Entrepreneurship, Bias, Human Reproduction (journal), Medical device, Mineral oil, Silviculture, Science

TEL AVIV, Israel, May 3, 2022 /PRNewswire/ -- Fairtility, the transparent AI innovator powering in vitro fertilization (IVF) for improved outcomes, announced the results of a new study published in Human Reproduction, "How slow is too slow? A comprehensive portrait of Day 7 blastocysts and their clinical value standardized through artificial intelligence," finding that ending embryo culture at 144 hours (six days) post-insemination (h.p.i.) would involve 7.3 percent and 4.4 percent relative reductions in the number of patients obtaining euploid blastocysts and live birth(s) (LBs), respectively.

Key Points: 
  • A comprehensive portrait of Day 7 blastocysts and their clinical value standardized through artificial intelligence," finding that ending embryo culture at 144hours (six days) post-insemination (h.p.i.)
  • would involve 7.3 percent and 4.4 percent relative reductions in the number of patients obtaining euploid blastocysts and live birth(s) (LBs), respectively.
  • "Fairtility's AI-powered tool can help IVF professionals make the most of time-lapse data through standardized and reproducible evaluations.
  • Here it made objective the clinical value of Day 7 embryos, opening up possibilities for couples struggling to get pregnant and to clinics contemplating a 6-to-7-day culture."

AlphaLogix announces market release of AlphaFlo® canine allograft

Retrieved on: 
Thursday, March 31, 2022
Endless Renovation, Multimedia, USP, Live birth, Tissue, Health, View, LLC, Equus, EAS, Dog, Animal, Allotransplantation, Amnion, Patient, Partnership, Vaccine, MD, Phoenix

PHOENIX, March 31, 2022 /PRNewswire/ -- Equus Innovations, a manufacturer of advanced, next-generation veterinary regenerative products, in partnership with AlphaLogix, LLC (Argyle, Texas) announced today successful market release of a new canine allograft, AlphaFlo.

Key Points: 
  • PHOENIX, March 31, 2022 /PRNewswire/ -- Equus Innovations, a manufacturer of advanced, next-generation veterinary regenerative products, in partnership with AlphaLogix, LLC (Argyle, Texas) announced today successful market release of a new canine allograft, AlphaFlo.
  • AlphaFlo is a liquid, acellular, canine amniotic tissue allograft comprised of amnion, intended to supplement and protect tissues.
  • Grant D. Senner, MD, DABRM and Equus Innovations' Chief Executive Officer stated, "The release of AlphaFlo by AlphaLogix is another exciting regenerative solution for veterinary patients.
  • AlphaLogix, LLC is a leading provider of next-generation canine veterinary products, including AlphaFlo.

Shady Grove Fertility (SGF) physician, Howard McClamrock, M.D., to be honored at 2021 Cade Foundation Family Building Gala

Retrieved on: 
Thursday, November 11, 2021
Quality of life, MPH, Reproductive medicine, University, Adoption, Fertility, Live birth, Education, Gala, EST, CEO, Maryland School, Fertilisation, Race, Investor, Organic, Insurance, Infertility, Family Building Society, Family, Research, University of Maryland School of Medicine, Partnership, Board, Awareness, Physician, IVF, Patient, SGF, Board of directors, Pharmaceutical industry, Birth control

ROCKVILLE, Md., Nov. 11, 2021 /PRNewswire-PRWeb/ -- Shady Grove Fertility (SGF) supports the Tinina Q. Cade Foundation as Platinum Sponsor of its hybrid Family Building Gala on November 13, 59 p.m. EST, where SGF physician, Howard McClamrock, M.D.

Key Points: 
  • ROCKVILLE, Md., Nov. 11, 2021 /PRNewswire-PRWeb/ -- Shady Grove Fertility (SGF) supports the Tinina Q. Cade Foundation as Platinum Sponsor of its hybrid Family Building Gala on November 13, 59 p.m. EST, where SGF physician, Howard McClamrock, M.D.
  • Through this award, the Cade Foundation celebrates physician leaders who have contributed to the field of reproductive medicine in meaningful and significant ways.
  • The Cade Foundation strives to raise $100,000 to continue its mission of serving families battling infertility by providing necessary information and financial support.
  • "I'm honored to be recognized at the Cade Foundation Family Building Gala and send congratulations and appreciation to all honorees who are dedicated to helping those struggling with infertility grow their families."

Cicero Diagnostics reaches 10,000-patient milestone with its ReceptivaDx™ Test

Retrieved on: 
Thursday, October 14, 2021
Health, Medical Devices, Other Health, Live birth, BCL6, Endometriosis, Reproductive medicine, Growth, Hormone, Infertility, Cicero, Inflammation, Patient, Failure, Society, IVF, American Society for Reproductive Medicine, Research, Female, Medical device, Pharmaceutical industry

Womens healthcare company, Cicero Diagnostics Inc., offering ReceptivaDx for unexplained infertility, implantation failure and recurrent pregnancy loss, today announced it has reached the 10,000-patient mark from fertility centers using ReceptivaDx and its signature BCL6 marker.

Key Points: 
  • Womens healthcare company, Cicero Diagnostics Inc., offering ReceptivaDx for unexplained infertility, implantation failure and recurrent pregnancy loss, today announced it has reached the 10,000-patient mark from fertility centers using ReceptivaDx and its signature BCL6 marker.
  • The milestone signifies substantial test growth since the companys inception and reflects the role ReceptivaDx now plays as a new standard of care in fertility centers helping patients who have experienced IVF failure.
  • Today ReceptivaDx is used by more than 350 fertility centers around the country and has been introduced in several strategic international markets with more expected, said Chris Jackson, CEO Cicero Diagnostics.
  • Cicero Diagnostics is the exclusive licensed provider of the BCL6 test for the detection of uterine lining dysfunction commonly associated with endometriosis.